Please assess the completion status of the following clinical trial:

Trial Title: Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV-1 infection by means of any one of the following:~Documentation of HIV diagnosis in the medical record by a licensed health care provider; OR HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating \>1000 RNA copies/mL; OR any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid Multispot antibody differentiation assay.~* On an Integrase Strand Transfer Inhibitor (INSTI) based regimen for at least 1 year and less than 5 years prior to screening~* Significant weight gain since initiation of the INSTI-based regimen (\>10% of baseline body weight)~* Viral load of \<200 copies/mL for \> 6 consecutive months prior to screening (single viral blips \<200 copies/mL accepted if re-suppressed)~* Documentation of weight, glycemia, cholesterol, and blood pressure (BP) history within the last year.~* Signed Informed Consent Form (Appendix B) and willing to comply with the protocol.~* Using proper contraception if of child bearing age and potential.~Exclusion Criteria:~* Pregnancy or desire to become pregnant within the next year~* Failure to use adequate contraception during the study if of child-bearing potential.~* Any underlying documented ART resistance to doravirine, tenofovir disoproxil fumarate, or lamivudine~* Prior virologic failure~* Concomitant drugs that interact with doravirine~* Initiated on concomitant drugs known to cause weight gain within the last 6 months (i.e. antidepressants and antipsychotics)~* Concomitant drugs known to cause nephrotoxicity~* History of renal toxicity or renal events while on TDF therapy.~* Creatinine clearance (CrCL) \< 50 mL/min~* Inability to read/understand English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DOR/3TC/TDF (Type: EXPERIMENTAL): 100mg of doravirine (DOR), 300mg of lamivudine (3TC), and 300mg of tenofovir disoproxil fumarate (TDF)

Based on this trial design, predict the completion outcome and termination type (if applicable).